The first dose of Sinopharm vaccine in the elderly with Parkinson's
disease was associated with death within the first 24 hours
Abstract
Severe Acute Respiratory Coronavirus Syndrome 2 (SARS-CoV-2) is a new
human coronavirus family discovered during the highly communicable
respiratory disease outbreak in Wuhan, China, in 2019. Various COVID-19
vaccines are up to 95% effective against symptomatic infections caused
by the COVID-19. Whether people with PD or PS have an increased risk of
COVID-19 and are associated with a higher risk of death is still
uncertain. In this study, we report eleven cases of PD patients who died
whitin 24 hours after vaccination with the Sinopharm. All patients were
over 79 years old (84.64 ± 5.08). All patients were SARS-CoV2 PCR
negative and took their first dose of the Sinopharm. All patients had a
duration of more than 5 years with PD. All patients presented to the
hospital less than 12 hours after vaccination. All patients died less
than 24 hours after vaccination. In this study, All the patients were
elderly and hypertension and diabetes were seen in 11 (100%) and 7
(63.6%) patients which could reinforce the hypothesis that older
patients with PD should be vaccinated more cautiously and these patients
should be discussed the vaccine with their physician especially in
patients who have other comorbidities. Because our report was a case
series study, we only identified patients, and the causality could not
be assumed or proven.